Healthcare professional

Does your role in healthcare touch on blood transfusions? Here you will find in-depth information on current issues and challenges in blood safety, and how the INTERCEPT™ Blood System provides a valuable and cost-effective solution to minimise the risk of transfusion-transmitted infection (TTI) through pathogen inactivation.

  • icon-bloodsafety2_0.png

    Blood safety

    Every day, blood saves thousands of lives around the world. But transfusion-transmitted infections (TTI) remain a risk: bacterial contamination in the first place, followed by the emergence of new pathogens or unknown variations.
    Read more about Blood Safety
  • icon-economics2_0.png

    Cost-effectiveness

    While pathogen-inactivated blood components are more expensive to produce than non-treated blood components, the INTERCEPT™ Blood System offers many cost-saving opportunities for hospitals.
    Read more about Cost-effectiveness
  • icon-intercept2_0.png

    INTERCEPT

    More than 100 blood centres worldwide count on the INTERCEPT™ Blood System to control the safety of platelets and plasma from whole blood and apheresis collections. INTERCEPT minimises the risk of transfusion-transmitted infection (TTI) through pathogen inactivation.
    Read more about INTERCEPT

Proven in Routine Use

Regulatory authorities concluded that INTERCEPT Platelets and Plasma are not clinically different from untreated products and may be prescribed and transfused in accordance with standard infusion methods.

The INTERCEPT Blood System is currently used to inactivate pathogens in platelets and plasma across Europe, CIS, the Middle East and USA.

The INTERCEPT™ Blood System is designed to reduce the risk of transfusion-transmitted diseases